The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TEVIMBRA (Beigene Aus Pty Ltd)
Product name
TEVIMBRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 (255 working days)
Active ingredients
tislelizumab
Registration type
NCE/ NBE
Indication
TEVIMBRA in combination with platinum-based chemotherapy is indicated for the firstline treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma with a PD-L1 expression ≥ 1% as determined by a validated test.